Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab

Authors :: Cingolani, A.
Tummolo, A. M.
Montemurro, G.
Gremese, E.
Larosa, L.
Cipriani, M. C.
Pasciuto, G.
Liperoti, R.
Murri, R.
Pirronti, T.
Cauda, R.
Fantoni, M.
Bellieni, A.
Brandi, V.
Calabrese, A.
Calvello, M. R.
Ciccullo, A.
Corbo, G.
Falsiroli, C.
Intini, E.
Landi, G.
Leone, P. M.
Macagno, F.
Martis, I.
Pais, C.
Potenza, A.
Salini, S.
Simonetti, J.
Taddei, E.
Tosato, M.
Varone, F.
Ventura, G.
Siciliano, M.
Source :: Infection
Publication Year :: 2020
Abstract: A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.

Tools